

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Valerie AUTIER et al. : Group Art Unit.: 1614
Serial No.: 10/541,493 : Examiner: HUGHES, Alicia R.
Filed: July 7, 2005 :
Title: KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF
DIABETES BY INCREASING THE NUMBER OF ISLETS OF LANGERHANS
CELLS

REPLY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SIR:

In response to the Office Action mailed on July 2, 2007, as a species for the disease, applicants elect with traverse non-insulin dependent diabetes.

The traversal is on the basis that the PTO has not established that it would pose an undue burden to examine the full scope of the application.

In accordance with M.P.E.P. 803.02, the Examiner is reminded that, should no prior art be found which renders the invention of the elected species unpatentable, the search of the remainder of the generic claim(s) should be continued in the same application. Since the decisions in *In re Weber*, 580 F.2d 455, 198 USPQ 328 (CCPA 1978) and *In re Haas*, 580 F.2d 461, 198 USPQ 334 (CCPA 1978), it is improper for the Office to refuse to examine that which applicants regard as their invention, unless the subject matter in a claim lacks unity of invention. See MPEP 803.02 in accord.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,

/Csaba Henter/

Csaba Henter, Reg. No. 50,908
Anthony J. Zelano, Reg. No. 27,969
Attorneys for Applicants

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Boulevard, Suite 1400
Arlington, VA 22201
Direct Dial: 703-812-5331
Facsimile: 703-243-6410
Attorney Docket No.:MERCK-3029

Date: August 17, 2007

K:\Merck\3000 - 3999\3029\Reply Aug 07.doc